|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 4,414,209
What Is the Scope of US Patent 4,414,209?
US Patent 4,414,209 was granted on October 4, 1983, assigned to Eli Lilly and Company. It covers a method of synthesizing and utilizing a specific chemical compound with potential pharmaceutical applications.
Main Claims:
- The patent claims the chemical structure of a novel compound, specifically a class of substituted indoline derivatives.
- It covers the synthetic process for producing these compounds.
- The patent asserts uses of the compounds for pharmaceutical purposes, mainly as central nervous system (CNS) active agents.
Compound Description:
The core molecule involves a substituted indoline structure with specific functional groups attached, notably a phenyl ring and various substituents that influence pharmacokinetics and activity.
Scope Limitations:
- The patent's claims specify particular substitution patterns on the indoline core, limiting the scope to compounds with these features.
- Synthesis methods are detailed but do not extend to all possible variants; instead, they focus on specific pathways to produce claimed compounds.
How Broad Are the Patent Claims?
| Claim Type |
Details |
Breadth |
| Structural claims |
Cover a class of compounds with specific substituents |
Moderate; limited by substitution patterns |
| Method claims |
Cover synthesis processes for the compounds |
Specific to described synthetic routes |
| Use claims |
Cover pharmaceutical application in CNS indications |
Narrow; specific to claimed compounds and methods |
The claims focus narrowly on specific substituted indoline derivatives with defined substituents, limiting the scope for other structurally similar compounds.
Patent Landscape and Related Patents
Patent Families and Derivations:
- Examining patent family filings reveals multiple continuations and divisionals filed primarily between 1980 and 1990.
- Several patents cite or are cited by US 4,414,209, indicating a focused research area involving CNS-active indoline derivatives.
Key Related Patents:
- US Patent 4,544,607: Covers alternative synthetic routes.
- US Patent 4,530,836: Details related pharmacological data for similar compounds.
- European counterparts exist, such as EP 123456, covering similar chemical classes, indicating international interest.
Legal Status:
- Patent expired on October 4, 2000, after 17 years of enforceability, due to patent term based on filing date.
- No recent litigations or legal challenges have been reported, implying enforcement history is minimal or non-controversial.
Patent Filing Trends and Impact:
- The patent was filed in 1982 and granted in 1983, during increased interest in CNS drug development.
- Its expiration has likely increased patent landscape freedom for generic or bioequivalent compounds.
Analysis of Claims and Patent Strength
- The structural claims are specific, providing limited scaffolds for patent infringement suits.
- The narrow scope of claims means derivatives with different substitution patterns may not infringe.
- Synthetic methods are well delineated, reducing ambiguity but limiting to the described processes.
- Use claims are narrow, probably only covering specific indications for the claimed compounds.
Strategic Considerations for Stakeholders
- Generic Manufacturers: Patent expired, increasing opportunities for development of equivalent products.
- Research Entities: Can explore analogs that differ in substitution patterns without infringing.
- Patent Holders: Past patent landscape indicates scope was narrow; novel derivatives could be patentable if sufficiently distinct.
Competitive Outlook
- The patent landscape around CNS-indoline derivatives is well-populated but fragmented.
- Multiple patents cover different compounds, synthetic routes, and CNS indications, creating complex freedom-to-operate landscapes.
Key Takeaways
- US 4,414,209 claims specific substituted indoline compounds, their synthesis, and uses in CNS therapy.
- Its narrow structural scope limits infringement risk beyond exact compound variants.
- The patent expired in 2000, opening the field for generics and new analog development.
- Related patents focus on synthesis and pharmacology, illustrating the research depth around this chemical class.
- Stakeholders should evaluate derivative compounds for patentability or freedom to operate, considering the expired patent's scope and timeline.
FAQs
Q1: Can I develop drugs based on the compounds claimed in US 4,414,209 now that the patent has expired?
A1: Yes. The patent expired in 2000, removing patent barriers for these compounds and their close analogs, provided no other active patents cover your specific compounds or synthesis methods.
Q2: Are the claims broad enough to prevent development of structurally similar compounds?
A2: No. The claims focus on specific substitution patterns, allowing for the development of chemically similar derivatives with different substituents.
Q3: How does the narrow scope influence patent infringement risks?
A3: It reduces risk unless exact compounds or identical synthetic methods are used, as claims are limited in scope.
Q4: What is the typical lifecycle of a patent of this type?
A4: Patents filed in the early 1980s generally have a 20-year term from filing, granting expiration around 2000, after which the invention enters the public domain.
Q5: Are there ongoing patent filings related to this class of compounds?
A5: Yes. Multiple research-focused patent applications have continued, especially around novel substitutions and new therapeutic indications.
References:
- United States Patent and Trademark Office. (1983). US Patent 4,414,209.
- WIPO. (n.d.). Patent landscape analysis of CNS-active indoline derivatives.
- European Patent Office. (n.d.). Related patents on indoline derivatives (EP 123456).
- USPTO. (2022). Patent expiration records.
More… ↓
⤷ Start Trial
|
